Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells

ACS Medicinal Chemistry Letters

Volumn 5, Issue 2, 2014, Pages 113-118

  Liu, Zi ^a,c   Ma, Liang ^a   Wen, Zhe Sheng ^b   Cheng, Yong Xian ^d   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

apoptosis; cell proliferation; CIP2A; Ethoxysanguinarine; lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CISPLATIN; ETHOXYSANGUINARINE; MYC PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SANGUINARINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

EID: 84894056181     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400341k     Document Type: Article

References (26)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics Ca-Cancer J. Clin. 2011, 61, 69-90
2. Molina, J. R.; Yang, P.; Cassivi, S. D.; Schild, S. E; Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clinic Proc. 2008, 83, 584-594 (Pubitemid 351720831)
3. Teng, H. W.; Yang, S. H.; Lin, J. K.; Chen, W. S.; Lin, T. C.; Jiang, J. K.; Yen, C. C.; Li, A. F. Y.; Chen, P. C. H.; Lan, Y. T.; Lin, C. C.; Hsu, Y. N.; Wang, H. W; Chen, K. F. CIP2A is a predictor of poor prognosis in colon cancer J. Gastrointest. Surg. 2012, 16, 1037-1047
4. Fang, Y. Y.; Li, Z. T.; Wang, X. X.; Zhang, S. L. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis Tumor Biol. 2012, 33, 2299-2306
5. Ma, L.; Wen, Z. S.; Liu, Z.; Hu, Z.; Ma, J.; Chen, X. Q.; Liu, Y. Q.; Pu, J. X.; Xiao, W. L.; Sun, H. D; Zhou, G. B. Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer PLoS One 2011, 6, e20159
6. Vaarala, M. H.; Vaisanen, M. R; Ristimaki, A. CIP2A expression is increased in prostate cancer J. Exp. Clin. Cancer Res. 2010, 29, 136
7. Khanna, A.; Bockelman, C.; Hemmes, A.; Junttila, M. R.; Wiksten, J. P.; Lundin, M.; Junnila, S.; Murphy, D. J.; Evan, G. I.; Haglund, C.; Westermarck, J.; Ristimaki, A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer J. Natl. Cancer. I 2009, 101, 793-805
8. Junttila, M. R.; Puustinen, P.; Niemela, M.; Ahola, R.; Arnold, H.; Bottzauw, T.; Ala-Aho, R.; Nielsen, C.; Ivaska, J.; Taya, Y.; Lu, S. L.; Lin, S. J.; Chan, E. K. L.; Wang, X. J.; Grenman, R.; Kast, J.; Kallunki, T.; Sears, R.; Kahari, V. M.; Westermarck, J. CIP2A inhibits PP2A in human malignancies Cell 2007, 130, 51-62 (Pubitemid 47039258)
9. Bockelman, C.; Lassus, H.; Hemmes, A.; Leminen, A.; Westermarck, J.; Haglund, C.; Butzow, R.; Ristimaki, A. Prognostic role of CIP2A expression in serous ovarian cancer Br. J. Cancer 2011, 105, 989-995
10. Ren, J.; Li, W.; Yan, L.; Jiao, W.; Tian, S.; Li, D.; Tang, Y.; Gu, G.; Liu, H.; Xu, Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival Br. J. Cancer 2011, 105, 1905-1911
11. Xu, P.; Xu, X. L.; Huang, Q.; Zhang, Z. H; Zhang, Y. B. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis Med. Oncol. 2012, 29, 1643-1647
12. Dong, Q. Z.; Wang, Y.; Dong, X. J.; Li, Z. X.; Tang, Z. P.; Cui, Q. Z; Wang, E. H. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis Ann. Surg. Oncol. 2011, 18, 857-865
13. Laine, A.; Sihto, H.; Come, C.; Rosenfeldt, M. T.; Zwolinska, A.; Niemela, M.; Khanna, A.; Chan, E. K.; Kahari, V. M.; Kellokumpu-Lehtinen, P. L.; Sansom, O. J.; Evan, G. I.; Junttila, M. R.; Ryan, K. M.; Marine, J. C.; Joensuu, H.; Westermarck, J. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1 Cancer Discovery 2013, 3, 182-197
14. Ventela, S.; Come, C.; Makela, J. A.; Hobbs, R. M.; Mannermaa, L.; Kallajoki, M.; Chan, E. K.; Pandolfi, P. P.; Toppari, J.; Westermarck, J. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice PLoS One 2012, 7, e33209
15. Lucas, C. M.; Harris, R. J.; Giannoudis, A.; Copland, M.; Slupsky, J. R; Clark, R. E. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression Blood 2011, 117, 6660-6668
16. Yu, H. C.; Chen, H. J.; Chang, Y. L.; Liu, C. Y.; Shiau, C. W.; Cheng, A. L.; Chen, K. F. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma Biochem. Pharmacol. 2013, 85, 356-366
17. Lin, Y. C.; Chen, K. C.; Chen, C. C.; Cheng, A. L; Chen, K. F. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells Oral Oncol. 2012, 48, 585-593
18. Konda, Y.; Urano, M.; Harigaya, Y.; Onda, M. Studies on the constituents of bocconia-cordata 0.4. Transformation of sanguinarine into bocconine J. Heterocyclic Chem. 1991, 28, 1841-1843
19. Hu, Z. B.; Xu, Y.; Feng, S. C.; Fan, G. J. [Studies on the active principles of the fruits of Macleaya cordata (Willd.) R. Br. (author's transl)] Yao Xue Xue Bao 1979, 14, 535-540
20. Miao, F.; Yang, X. J.; Zhou, L.; Hu, H. J.; Zheng, F.; Ding, X. D.; Sun, D. M.; Zhou, C. D.; Sun, W. Structural modification of sanguinarine and chelerythrine and their antibacterial activity Nat. Prod. Res. 2011, 25, 863-875
21. Li, W. G.; Dai, F. Y.; Cheng, Y. X.; Yin, G. F.; Bi, J. L.; Li, D. P. Identification of porcine reproductive and respiratory syndrome virus inhibitors through an oriented screening on natural products Chem. Res. Chin. U. 2013, 29, 290-293
22. Liu, L. Z.; Zhou, X. D.; Qian, G.; Shi, X.; Fang, J.; Jiang, B. H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway Cancer Res. 2007, 67, 6325-6332 (Pubitemid 47037515)
23. Westermarck, J.; Hahn, W. C. Multiple pathways regulated by the tumor suppressor PP2A in transformation Trends Mol. Med. 2008, 14, 152-160
24. Liu, Z.; Ma, L.; Wen, Z. S.; Hu, Z.; Wu, F. Q.; Li, W.; Liu, J.; Zhou, G. B. Cancerous inhibitor of PP2A (CIP2A) is targeted by natural compound celastrol for degradation in non-small-cell lung cancer Carcinogenesis 2013, 10.1093/carcin/bgt395
25. Chen, K. F.; Liu, C. Y.; Lin, Y. C.; Yu, H. C.; Liu, T. H.; Hou, D. R.; Chen, P. J.; Cheng, A. L. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells Oncogene 2010, 29, 6257-6266
26. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 2003, 22, 7265-7279 (Pubitemid 37487159)